RESUMO
We present a case of a 54-year-old woman who was diagnosed with a KRAS positive adenocarcinoma of the lung on the basis of a Peutz-Jeghers syndrome (PJS), which was unknown before. PJS is a rare hereditary disease, which may be associated with the development of poor outcome adenocarcinomas and LKB1-gene mutations. A very rare type of a LKB1 mutation was found, not previously described in lung cancer. Although seldom screened for LKB-1 mutations are found in up to 30% of lung adenocarcinomas and may be druggable therapeutic targets, in particular in KRAS mutant tumours in the near future as recent preclinical results with nucleotides demonstrate.
Assuntos
Adenocarcinoma/complicações , Adenocarcinoma/genética , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/genética , Síndrome de Peutz-Jeghers/complicações , Proteínas Serina-Treonina Quinases/genética , Proteínas ras/genética , Quinases Proteína-Quinases Ativadas por AMP , Adenocarcinoma/diagnóstico , Adenocarcinoma de Pulmão , Evolução Fatal , Feminino , Humanos , Hiperpigmentação , Lábio/patologia , Pulmão/diagnóstico por imagem , Pulmão/patologia , Neoplasias Pulmonares/diagnóstico , Pessoa de Meia-Idade , Tomografia Computadorizada por Raios XRESUMO
Hyponatremia is frequently observed on the basis of syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH) in patients suffering from lung cancer. This electrolyte imbalance is associated with higher mortality and morbidity. If hyponatremia influences survival of lung cancer remains controversial. In the current study we retrospectively analysed if survival is directly impacted by hyponatremia and evaluated if hyponatremia is a prognostic marker for lung cancer.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma de Células Pequenas/mortalidade , Hiponatremia/mortalidade , Neoplasias Pulmonares/mortalidade , Adulto , Idoso , Carcinoma Pulmonar de Células não Pequenas/sangue , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma de Células Pequenas/sangue , Carcinoma de Células Pequenas/patologia , Feminino , Humanos , Hiponatremia/sangue , Síndrome de Secreção Inadequada de HAD/sangue , Síndrome de Secreção Inadequada de HAD/mortalidade , Neoplasias Pulmonares/sangue , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Fatores de Risco , Sódio/sangue , Análise de SobrevidaRESUMO
Over the last years, several new systemic cancer therapy strategies have been introduced to turn the growing insights of molecular aberrations involved in the development and progression of lung cancer into better treatment options fort the patients. This review presents some of the most important biological targets and biomarkers relevant in the treatment of non-small cell lung cancer. Especially EGFR mutations, anti-angiogenesis, multi kinase inhibition, vascular disrupting agents, vaccines, m-TOR inhibitors, TRAIL inhibition and several biomarkers are highlighted including current study results.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Inibidores da Angiogênese/uso terapêutico , Receptores ErbB/antagonistas & inibidores , Humanos , Proteínas Tirosina Quinases/antagonistas & inibidoresRESUMO
The treatment and medical care of patients with lung cancer is mostly characterised and complicated by a reduced life expectancy. The lack of time can easily be the cause for various problems concerning the handling of these patients, their relatives and medical staff. A concept for opening future perspectives through standardised steps of communication could lead to a more cautious and humane relationship between physician and patient. In the case of successful realisation of this strategy, a significant enhancement of quality of life for the patient and relatives and practicability of work for the physician can be expected.
